340 related articles for article (PubMed ID: 23242139)
1. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Ruark E; Snape K; Humburg P; Loveday C; Bajrami I; Brough R; Rodrigues DN; Renwick A; Seal S; Ramsay E; Duarte Sdel V; Rivas MA; Warren-Perry M; Zachariou A; Campion-Flora A; Hanks S; Murray A; Ansari Pour N; Douglas J; Gregory L; Rimmer A; Walker NM; Yang TP; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Eccles D; Evans DG; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; Gore M; Houlston R; Brown MA; Caufield MJ; Deloukas P; McCarthy MI; Todd JA; ; ; Turnbull C; Reis-Filho JS; Ashworth A; Antoniou AC; Lord CJ; Donnelly P; Rahman N
Nature; 2013 Jan; 493(7432):406-10. PubMed ID: 23242139
[TBL] [Abstract][Full Text] [Related]
2. Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.
Machiela MJ; Myers TA; Lyons CJ; Koster R; Figg WD; Colli LM; Jessop L; Ahearn TU; Freedman ND; García-Closas M; Chanock SJ
J Hum Genet; 2019 Jun; 64(6):545-550. PubMed ID: 30850729
[TBL] [Abstract][Full Text] [Related]
3. PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Pharoah PDP; Song H; Dicks E; Intermaggio MP; Harrington P; Baynes C; Alsop K; ; Bogdanova N; Cicek MS; Cunningham JM; Fridley BL; Gentry-Maharaj A; Hillemanns P; Lele S; Lester J; McGuire V; Moysich KB; Poblete S; Sieh W; Sucheston-Campbell L; Widschwendter M; ; Whittemore AS; Dörk T; Menon U; Odunsi K; Goode EL; Karlan BY; Bowtell DD; Gayther SA; Ramus SJ
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26823519
[TBL] [Abstract][Full Text] [Related]
4. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Swisher EM; Harrell MI; Norquist BM; Walsh T; Brady M; Lee M; Hershberg R; Kalli KR; Lankes H; Konnick EQ; Pritchard CC; Monk BJ; Chan JK; Burger R; Kaufmann SH; Birrer MJ
JAMA Oncol; 2016 Mar; 2(3):370-2. PubMed ID: 26847329
[TBL] [Abstract][Full Text] [Related]
5. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Kim B; Won D; Lee ST; Choi JR
PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196
[TBL] [Abstract][Full Text] [Related]
6. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Akbari MR; Lepage P; Rosen B; McLaughlin J; Risch H; Minden M; Narod SA
J Natl Cancer Inst; 2014 Jan; 106(1):djt323. PubMed ID: 24262437
[TBL] [Abstract][Full Text] [Related]
7. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
8. A Case Study on PPM1D and 9 Other Shared Germline Alterations in a Family.
Biswas S; Manekar S; Bakshi SR
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2129-2134. PubMed ID: 37378944
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
10. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
11. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
12. De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.
Jansen S; Geuer S; Pfundt R; Brough R; Ghongane P; Herkert JC; Marco EJ; Willemsen MH; Kleefstra T; Hannibal M; Shieh JT; Lynch SA; Flinter F; FitzPatrick DR; Gardham A; Bernhard B; Ragge N; Newbury-Ecob R; Bernier R; Kvarnung M; Magnusson EA; Wessels MW; van Slegtenhorst MA; Monaghan KG; de Vries P; Veltman JA; ; Lord CJ; Vissers LE; de Vries BB
Am J Hum Genet; 2017 Apr; 100(4):650-658. PubMed ID: 28343630
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
[TBL] [Abstract][Full Text] [Related]
14. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
Lu X; Bocangel D; Nannenga B; Yamaguchi H; Appella E; Donehower LA
Mol Cell; 2004 Aug; 15(4):621-34. PubMed ID: 15327777
[TBL] [Abstract][Full Text] [Related]
15. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
17. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
18. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
19. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
[TBL] [Abstract][Full Text] [Related]
20. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
